Prion Capture Technology
ProMetic’s Pathogen Removal and Diagnostic Technologies (“PRDT”), an affiliate of PBL based in Delaware, USA, operates a prion capture technology that was originally developed from ProMetic’s collaboration with the American Red Cross.
PRDT is responsible for the development and commercialization of this platform technology, which has demonstrated its potential for uses in the purification of blood-derived products.
Upwards of forty million units of blood are collected in the world annually which provides ProMetic and its strategic partners enormous market opportunities.
Please see the below examples prion capture technology’s capabilities.
P Capt® filter is a prion reduction device to increase the safety of red cell concentrate, which has received CE mark approval in Europe.
ProMetic has developed P Capt® alongside its commercial partner MacoPharma with PRDT’s technology underpinning the device, enabling the detection of the blood-borne form variant Creutzfeldt-Jakob disease (“vCJD”) transmission through blood transfusion.
There is no commercially available diagnostic test for vCJD; therefore, P Capt® can provide national blood agencies with the means to significantly reduce the risk of vCJD.
P Capt® has received CE mark approval in Europe, and can provide national blood agencies with the means to significantly reduce the risk of
PrioClear™ is a range of prion binding affinity resins that is used commercially to increase the safety of blood and blood derived products.
Through its proven affinity technologies PRDT has aided in the design and development of a panel of affinity adsorbents to enable the highly effective capture of prion from a range of biological materials.
OctaplasLG® is a solvent/detergent treated plasma product. Octapharma AG has incorporated PRDT technology into its manufacturing process to further improve the prion safety margin for this plasma product.
OctaplasLG® has obtained regulatory approval in several European countries (including Germany and the UK), the United States of America and Australia.